Charles Schwab Investment Management Inc. Has $2.18 Million Stake in Vanda Pharmaceuticals Inc. $VNDA

Charles Schwab Investment Management Inc. lowered its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 14.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 475,865 shares of the biopharmaceutical company’s stock after selling 82,581 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.81% of Vanda Pharmaceuticals worth $2,184,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of VNDA. Schonfeld Strategic Advisors LLC bought a new stake in Vanda Pharmaceuticals in the 4th quarter valued at about $1,296,000. Millennium Management LLC increased its position in shares of Vanda Pharmaceuticals by 67.4% in the fourth quarter. Millennium Management LLC now owns 668,693 shares of the biopharmaceutical company’s stock worth $3,203,000 after purchasing an additional 269,183 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Vanda Pharmaceuticals by 10.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,488,519 shares of the biopharmaceutical company’s stock worth $11,920,000 after purchasing an additional 227,428 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Vanda Pharmaceuticals in the first quarter worth approximately $875,000. Finally, GSA Capital Partners LLP boosted its stake in Vanda Pharmaceuticals by 88.0% in the first quarter. GSA Capital Partners LLP now owns 260,215 shares of the biopharmaceutical company’s stock worth $1,194,000 after buying an additional 121,797 shares in the last quarter. 88.14% of the stock is owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Trading Up 0.6%

Shares of VNDA opened at $4.73 on Friday. The business’s 50 day moving average is $4.63 and its 200 day moving average is $4.53. The company has a market capitalization of $279.50 million, a PE ratio of -4.19 and a beta of 0.72. Vanda Pharmaceuticals Inc. has a 12-month low of $3.81 and a 12-month high of $5.55.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.12). The business had revenue of $52.59 million for the quarter, compared to the consensus estimate of $54.77 million. Vanda Pharmaceuticals had a negative net margin of 32.90% and a negative return on equity of 12.89%. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Wall Street Zen downgraded Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Saturday, August 2nd. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a report on Thursday, August 21st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price target on shares of Vanda Pharmaceuticals in a report on Wednesday, May 14th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Strong Buy” and a consensus price target of $16.50.

Insider Buying and Selling at Vanda Pharmaceuticals

In other news, Director Stephen Ray Mitchell sold 7,000 shares of the business’s stock in a transaction on Friday, June 13th. The stock was sold at an average price of $4.59, for a total value of $32,130.00. Following the completion of the transaction, the director directly owned 97,082 shares of the company’s stock, valued at approximately $445,606.38. The trade was a 6.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 10.00% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.